Premium
O4‐07‐01: T807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase a
Author(s) -
Vermeiren Céline,
Mercier Joël,
Viot Delphine,
Mairet-Coello Georges,
Hannestad Jonas,
Courade Jean-Philippe,
Citron Martin,
Gillard Michel
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.381
Subject(s) - clorgyline , chemistry , recombinant dna , binding site , monoamine oxidase b , biophysics , biochemistry , monoamine oxidase , binding selectivity , ligand (biochemistry) , receptor , enzyme , biology , gene
to determine the legal implications of biomarkers for insurance or employment purposes. Federal law prohibiting employment discrimination based on disability offered potential protections for individuals. Comparatively, federal law explicitly delegates insurance regulation to states. Regulations vary between states on issues regarding underwriting, eligibility, and benefits. Additionally, while the Affordable Care Act provides protections regarding health insurance by prohibiting discrimination based on pre-existing conditions, similar protections are not extended for life, disability, or long-term care insurance. Conclusions: Current laws are largely insufficient to protect individuals from employment or insurance discrimination based on preclinical Alzheimer’s disease status. This supports exploring the potential routes for advocacy to improve protections and research regarding other routes for mitigating the potential risks related to insurance and employment. This work was supported by a grant from the Alzheimer’s Association (MNIRGD-14-319284).